Cover Image
市場調查報告書

中國的胰島素市場相關詳細評估與預測

Research and Forecast on China Insulin Market, 2014-2018

出版商 Huidian Research 商品編碼 300033
出版日期 內容資訊 英文 65 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的胰島素市場相關詳細評估與預測 Research and Forecast on China Insulin Market, 2014-2018
出版日期: 2014年04月15日 內容資訊: 英文 65 Pages
簡介

中國的胰島素市場規模2013年達110億人民幣。其中75億人民幣來自第2代的胰島素市場,35億人民幣來自第3代胰島素市場。新的第3代胰島素市場比第2代胰島素急速成長。全球擁有全部系列的胰島素產品的只有2家公司,其中一家是Tonghua Dongbao。該公司與Novo Mordisk、Eli Lilly並列為生產第2代胰島素的3家公司之一。

本報告提供中國的胰島素市場相關調查、發展歷史、政策環境、進出口趨勢、新產品概要、主要參與企業簡介等彙整資料,為您概述為以下內容。

第1章 胰島素概要

  • 糖尿病概要與關聯的治療藥狀況
    • 糖尿病概要
    • 糖尿病的臨床性運類
    • 主要的治療藥、臨床性影響、治療策略
  • 胰島素的定義與分類
  • 中國胰島素的發展歷史
    • 第1代胰島素
    • 第2代的胰島素
    • 第3代胰島素

第2章 中國的胰島素市場商業環境

  • 2013年的中國經濟環境
  • 2013年的政策環境
    • 對加深醫療及衛生制度改革的見解
    • 為了加深第12次5年計劃的醫療及衛生制度改革之計劃和實施
    • 使用胰島素的教育管理標準
    • 2013年的第二型糖尿病的預防指南
    • 醫藥品的抗凝固劑
  • 2013年的技術環境
    • 胰島素幫浦
    • 在臨床試驗階段使用幹細胞移植的糖尿病治療
  • 中國消費者對胰島素的見解

第3章 2013年的中國胰島素市場趨勢

  • 現狀
    • 中國及海外糖尿病的發展趨勢
    • 市場規模
  • 2013年的中國胰島素產業的新模式

第4章 中國的胰島素產品市場區隔的進出口資料

  • 胰島素和食鹽的進出口資料
  • 一日服用量未定的含胰島素藥物的出口資料
  • 決定一日服用量的含胰島素的進出口資料

第5章 主要企業

  • Tonghua Dongbao
  • Wanbang Biopharmaceuticals
  • United Laboratories
  • Gan & Lee
  • Yabao Pharmaceutical Group
  • Novo Nordisk
  • Eli Lilly and Company
  • SANOFI

第6章 中國的胰島素市場發展趨勢與預測

  • 發展預測
    • 巨大的胰島素市場潛在性
    • 口服胰島素市場潛在性
  • 發展趨勢
    • 政策環境的變化的企業的研究開發機會與課題
    • 胰島素產品的開發趨勢
  • 2014∼2018年的中國的胰島素市場預測
目錄

Research and Forecast on China Insulin Market, 2014-2018 carries on a thorough analysis of development history, policy environment, import and export, new products and key enterprises of China Insulin Market.

A survey conducted by Huidian Research shows that China's insulin market scale approximately registered CNY 11 billion in 2013, of which CNY 7.5 billion achieved in second-generation insulin market and CNY 3.5 billion generated in third-generation insulin market. Now third-generation insulin market grows faster than second-generation insulin. And second-generation insulin market will accelerate growing space because it is just listed into new essential drug catalogue.

Currently there are only two companies owning full series of insulin products globally, Tonghua Dongbao is one of the two. As for global insulin market at present, only three companies, including Tonghua Dongbao, Novo Nordisk and Eli Lilly, produce second-generation insulin in quantity. Under oligopolistic competition in the global market, it is difficult to tell which companies' products are better, but Tonghua Dongbao enjoys the lowest overall production cost. Compared with expensive insulin produced by transnational giants, governments can reduce expenditure of health insurance if buying Dongbao's insulin, so Tonghua Dongbao will become a powerful contender when competing for more market shares with transnational giants in the developing countries.

Four domestic companies obtained production approval of second-generation insulin, namely United Laboratories, Donghua Tongbao, Wanbang and Shenzhen Kexing Biotech. The latter two received production approval in 2003, but their products did not sell in market due to bad quality. Currently Wanbang's animal insulin injections enjoy the largest sales volume in China.

Third-generation insulin in foreign market covers rapid-acting insulin (insulin aspart and insulin lispro) and long-acting insulin (insulin glargine and insulin detemir). Recombinant insulin lispro and its injection, which are high-end products, also belong to third-generation insulin. Third-generation insulin is quicker to take effects and also can better simulate physiologic insulin secretion pattern. Information disclosed by China Food and Drug Administration show that Eli Lilly and Company and Gan & Lee (a private company in China) owns production approval documents of this type of insulin. Affected by its commercial bribery case, business performance of Gan & Lee witnessed a significant drop in 2013, but its third-generation insulin that is a foreign-funded brand with dominant position in market had not been influenced much.

Huidian Research holds a view that for now third-generation insulin is superior in effects but its price is far higher than second-generation insulin, so low and middle income patients without medical insurance are hard to pay for the expensive drug cost. So in wide grass roots market, second-generation insulin enjoys an overwhelming superiority. But it is predicated that with the decreasing price, third-generation insulin will replace second-generation insulin in the next years, representing the general trend.

Table of Contents

1. Overview of Insulin

  • 1.1. Brief Introduction to Diabetes & General Situation of Related Therapeutic Drugs
    • 1.1.1. Overview of Diabetes
    • 1.1.2. Clinical Classification of Diabetes
    • 1.1.3. Major Therapeutic Drugs, Clinical Effects and Treatment Strategy
  • 1.2. Definition and Classification of Insulin
    • 1.2.1. Definition
    • 1.2.2. Classification
  • 1.3. Development History of Insulin in China
    • 1.3.1. First-Generation Insulin (Multi-component Insulin Extracted from Animal Pancreas)
    • 1.3.2. Second-Generation Insulin (Insulin Human)
    • 1.3.3. Third-Generation Insulin (Improved Insulin or Insulin Analogues)

2. Operation Environment of China Insulin Market in 2013

  • 2.1. China's Economic Environment in 2013
  • 2.2. Policy Environment in 2013
    • 2.2.1. Opinions Concerning Deepening Medical and Health System Reform
    • 2.2.2. Planning and Implementation of Deepening Medical and Health System Reform During the 12th Five-Year Plan
    • 2.2.3. Comprehensive Improved Standards for Insulin and Recombinant Human Insulin in Chinese Pharmacopoeia 2010
    • 2.2.4. Educational Management Standards for Using Insulin
    • 2.2.5. Prevention Guideline of Type 2 Diabetes Mellitus in 2013
    • 2.2.6. Continuous Anti-corruption in Medicine
  • 2.3. Technological Environment in 2013
    • 2.3.1. Insulin Pump
    • 2.3.2. Diabetes Treatment by Using Stem Cell Transplantation is on Clinical Test Stage
  • 2.4. Chinese Consumers' Cognition toward Insulin

3. Trend of China Insulin Market in 2013

  • 3.1. Current Situation
    • 3.1.1. Development Status of Diabetes in China and at Overseas
    • 3.1.2. Market Scale
  • 3.2. New Pattern of China Insulin Industry in 2013

4. Import and Export Data of Product Segments of Insulin in China, 2011-2013

  • 4.1. Import and Export Data of Insulin and Its Salt in China, 2011-2013 (HS Code: 293712)
  • 4.2. Export Data of Drugs Containing Insulin without Defined Daily Doses, 2011-2013 (HS Code: 300331)
  • 4.3. Import and Export Data of Drugs Containing Insulin with Defined Daily Doses, 2011-2013 (HS Code: 300431)

5. Key Enterprises in Insulin Industry

  • 5.1. Tonghua Dongbao
    • 5.1.1. Company Profile
    • 5.1.2. Business Performance
    • 5.1.3. Main Business Composition
    • 5.1.4. Progress of Research and Development
    • 5.1.5. Channel Expansion
    • 5.1.6. Development Plan in 2014
  • 5.2. Wanbang Biopharmaceuticals
    • 5.2.1. Company Profile
    • 5.2.2. Business Performance
    • 5.2.3. Third-Generation Insulin Approved to be used in Clinical Test
    • 5.2.4. Marketing Network
    • 5.2.5. Growth Pattern in the Next Five Years
  • 5.3. United Laboratories
    • 5.3.1. Company Profile
    • 5.3.2. Business Performance
    • 5.3.3. Production Capacity
    • 5.3.4. New Products
    • 5.3.5. Marketing Promotion Channel
    • 5.3.6. Future Development Strategy
  • 5.4. Gan & Lee
    • 5.4.1. Company Profile
    • 5.4.2. Business Performance
    • 5.4.3. Commercial Bribery Case
    • 5.4.4. Business Channel Expands to County-level Central Hospitals
  • 5.5. Yabao Pharmaceutical Group
    • 5.5.1. Company Profile
    • 5.5.2. Channel Building
    • 5.5.3. Research & Development
  • 5.6. Novo Nordisk
    • 5.6.1. Company Profile
    • 5.6.2. Business Performance
    • 5.6.3. Enterprise R&D
  • 5.7. Eli Lilly and Company
    • 5.7.1. Company Profile
    • 5.7.2. Progress of R&D
    • 5.7.3. Overall Increase of Insulin Production Capacity in China
    • 5.7.4. Business Condition
    • 5.7.5. Channel Expansion
  • 5.8. SANOFI
    • 5.8.1. Company Profile
    • 5.8.2. R&D Framework
    • 5.8.3. Enterprise Operation

6. Development Trend and Prospect Forecast of China Insulin Market, 2014-2018

  • 6.1. Development Prospect
    • 6.1.1. Enormous Insulin Market Potential
    • 6.1.2. Huge Oral Insulin Market Potential
  • 6.2. Development Trend
    • 6.2.1. Opportunities and Challenges for Enterprise R&D brought by Policy Environment Change
    • 6.2.2. Development Trend of Insulin Products
  • 6.3. China Insulin Market Forecast from 2014 to 2018
Back to Top